Photo: Yana Iskayeva/Getty Images
Barcelona-based INBRAIN Neuroelectronics, which offers a graphene-based brain-computer interface (BCI) therapeutics platform, announced a strategic partnership with tech giant Microsoft to advance the use of agentic AI in precision neurology and through BCI technology.
INBRAIN says it offers a neural platform "built on graphene, a single layer of carbon atoms known for its exceptional conductivity, biocompatibility and precision."
The Spanish company will use Microsoft's Azure, including its large language models (LLMs) and data analytics capabilities, to enable its platform to continuously learn and adapt according to an individual patient's neural signals.
Agentic AI is an autonomous AI system that plans, reasons and acts without human oversight to achieve complex goals.
INBRAIN states that merging its decoding and modulation with agentic AI has the potential to transform the monitoring and treatment of neurological disorders by offering closed-loop precision interventions for diseases such as Parkinson's disease, memory disorders and epilepsy.
The collaborators also said they will develop AI-driven brain-computer interface treatments that can adjust neural circuits in real time based on individualized data, potentially enabling innovative therapies for specific organs.
"Our vision is to create the most intelligent, autonomous and personalized interface between the nervous system and AI," Carolina Aguilar, CEO and cofounder of INBRAIN Neuroelectronics, said in a statement.
"By collaborating with Microsoft, we’re combining our precision graphene neural technology with one of the world’s most powerful AI ecosystems. This partnership brings us closer to a future where brain-computer interfaces don’t just decode or modulate, but truly understand and respond to the nervous system in real time, making the nervous system the body OS."
THE LARGER TREND
In September, INBRAIN announced the formation of a U.S. subsidiary alongside the signing of a know-how collaboration agreement with Mayo Clinic.
Through the partnership, experts at Mayo Clinic will work with INBRAIN to accelerate the development and commercialization of INBRAIN's BCI therapeutics for patients with neurological disorders and evaluate the BCI-Tc in an IRB-approved setting.
"With Mayo Clinic’s clinical know-how, alongside other leading U.S. and European centers, we seek to validate our platform in real-world workflows, accelerate evidence generation, and move responsibly toward patient-focused BCI therapeutics," Aguilar said in a statement.
In May, the BCI company was awarded a €4 million ($4.63 million) grant by the Spanish Ministry of Industry and Tourism through the PERTE Chip initiative to accelerate the development of its BCI technology.
Upon news of the collaboration, Microsoft's stock [NASDAQ: MSFT] jumped 1.85% and is now trading at around $506 per share.
The HIMSS AI & Cybersecurity Virtual Forum is free to attend on Nov. 18. Learn more and register.
